Fresenius SE & Co. KGaA / Key word(s): Final Results 25.02.2014 07:00 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1 billion - Positive Group outlook for 2014 In 2013, Group sales increased by 5% (constant currency: 8%) to EUR20,331 million (2012: EUR19,290 million. Organic sales growth was 4%. Acquisitions contributed 5%. Divestitures reduced sales growth by 1%. Currency translation had a negative effect of 3%. Group EBIT* was EUR3,045 million, an increase of 1% in constant currency (2012: EUR3,075 million). The EBIT margin was 15.0% (2012: 15.9%). Group net income** increased by 12% (14% in constant currency) to EUR1,051 million (2012: EUR938 million). Earnings per share** increased by 8% to EUR5.88 (2012: EUR5.42). Group net income attributable to shareholders of Fresenius SE & Co. KGaA including Fenwal integration costs was EUR1,011 million or EUR5.66 per share. Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 14 % to EUR1.25 per share (2012: EUR1.10). The total dividend distribution is expected to be EUR225 million. For 2014, Fresenius projects sales growth of 12% to 15% in constant currency. Net income*** is expected to increase by 2% to 5% in constant currency. The Group's U.S. GAAP financial results as of December 31, 2013 are adjusted for Fenwal integration costs. Adjusted earnings represent the Group's business operations in the reporting period. * 2013 before Fenwal integration costs (EUR54 million); 2012 before one-time effects ** Net income attributable to shareholders of Fresenius SE & Co. KGaA ; 2013 before integration costs for Fenwal (EUR40 million); 2012 before one-time effects *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs for Fenwal (EUR30-40 million) and the hospitals acquired from Rhön-Klinikum AG (vast majority of ~EUR65 million in total); 2013 before Fenwal integration costs (EUR40 million) The 2014 guidance includes contributions from the acquisition of hospitals from Rhön-Klinikum AG. (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., February 25, 2014 End of note 25.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------